Advancing A Comprehensive Strategy for Immunogenicity Cut Point Evaluation

The assessment and implementation of in-study cut points for anti-drug antibody (ADA) assays are critical for accurate immunogenicity evaluation in clinical trials. Regulatory guidelines emphasize the importance of confirming the suitability of assay cut points for the study population, as differences in background activity can occur due to various factors including study-population demographics, disease state, and sample handling. This manuscript presents a strategy for assessing, implementing, and documenting in-study anti-drug antibody (ADA) assay cut points throughout clinical development. The strategy addresses the complexities introduced by multiple sequential or simultaneous clinical studies and different disease indications, suggesting process-management tools to ensure timely and accurate data analysis,interpretation, and documentation. Emphasis is placed on the importance of baseline sample assessment, statistical derivation of cut points, careful decision-making based on observed positive rates and comparisons to established disease-specific cut points, potential re-evaluation of assay validation parameters, as well as appropriate documentation. The framework provides a robust,scientifically sound approach for managing ADA assay cut points throughout the clinical development of recombinant protein therapeutics.